The ever-expanding landscape of antibody-drug conjugates (ADCs) in solid tumors: A systematic review.
Crit Rev Oncol Hematol
; 192: 104189, 2023 Dec.
Article
em En
| MEDLINE
| ID: mdl-37866413
ABSTRACT
BACKGROUND:
The advent of targeted therapies signaled novel avenues for more optimal oncological outcomes. Antibody-drug conjugates (ADCs) have risen as a cornerstone of the ever-expanding targeted therapy era. The purpose of this systematic review is to delineate the rapidly evolving clinical landscape of ADCs for solid tumors.METHODS:
A literature search was performed in Medline, Embase and Cochrane databases for phase II and III clinical trials. Outcomes of interest were the objective response rate, overall survival, progression-free survival and adverse events.RESULTS:
A total of 92 clinical trials (76 phase II and 16 phase III) evaluated the efficacy and safety of ADCs for a plethora of solid tumors. Out of the 30 investigated ADCs, 8 have received approval by regulatory organizations for solid tumors. Currently, 52 phase III clinical trials for ADCs are ongoing.CONCLUSION:
ADCs have shown promising results for several solid tumors and various cancer settings.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Temas:
Geral
/
Tipos_de_cancer
/
Outros_tipos
Base de dados:
MEDLINE
Assunto principal:
Imunoconjugados
/
Neoplasias
/
Antineoplásicos
Tipo de estudo:
Systematic_reviews
Limite:
Humans
Idioma:
En
Revista:
Crit Rev Oncol Hematol
Assunto da revista:
HEMATOLOGIA
/
NEOPLASIAS
Ano de publicação:
2023
Tipo de documento:
Article